The cancer center utilizes developmental funds to recruit new faculty to areas of Inquiry that may not have all of the desirable disciplines represented, to stimulate pilot studies (on occasion directed towards topics that the Senior Leadership considers to be important or fertile), and to create prototype shared resources. Thus, Developmental Funds are used to improve the scope and depth of cancer-related research at UC Davis and through its integrated cancer program with the Lawrence Livermore National Laboratory, the scope and depth of collaborative scientific undertakings.

Public Health Relevance

Cancer research is not static and new opportunities or challenges arise, and there Is a continuing need as well to cultive new scientific leadership;through Developmental Funds, the center is able to address changes In cancer research, new areas that promise new therapies, and build a complement of highly productive scientists across a broad spectrum of cancer-related research interests.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743637
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$305,201
Indirect Cost
$106,359
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Long, Qilai; Lin, Tzu-Yin; Huang, Yee et al. (2018) Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine 14:789-799
Gandara, David R; Riess, Jonathan W; Lara Jr, Primo N (2018) In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol 4:1197-1198
Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74

Showing the most recent 10 out of 836 publications